Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Tempest Therapeutics, Inc. (OVAS)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/10/2023 |
8-K
| Quarterly results|
Docs:
|
"Tempest Reports Second Quarter 2023 Financial Results and Provides Business Update Brisbane, CA, August 10, 2023 – Tempest Therapeutics, Inc. , a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted and immune-mediated mechanisms, today reported financial results for the quarter ended June 30, 2023 and provided a corporate update. “2023 continues to be a productive and potentially transformative year for Tempest,” said Stephen Brady, chief executive officer of Tempest. “In the second quarter, we presented data from our second clinical program, TPST-1495, the company’s novel dual EP2/EP4 antagonist designed to selectively modulate the prostaglandin pathway, both at ASCO and in a paper published in Cancer Research Communicati..." |
|
| 05/10/2023 |
8-K
| Quarterly results|
Docs:
|
"Tempest Reports First Quarter 2023 Financial Results and Provides Business Update Brisbane, CA, May 10, 2023 – Tempest Therapeutics, Inc. , a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted and immune-mediated mechanisms, today reported financial results for the quarter ended March 31, 2023 and provided a corporate update. “The first few months of 2023 set the pace for what we believe will be a transformative year for Tempest,” said Stephen Brady, chief executive officer of Tempest. “Recently, we announced exciting early data showing that TPST-1120, the company’s PPAR⍺ antagonist, combined with standard of care in first-line HCC patients demonstrated clinically meaningful improvement in multiple categories, incl..." |
|
| 03/22/2023 |
8-K
| Quarterly results |
| 11/08/2022 |
8-K
| Quarterly results |
| 08/15/2022 |
8-K
| Quarterly results |
| 05/13/2022 |
8-K
| Quarterly results |
| 03/29/2022 |
8-K
| Quarterly results |
| 11/10/2021 |
8-K
| Quarterly results |
| 08/12/2021 |
8-K
| Quarterly results |
| 03/29/2019 |
8-K
| Quarterly results |
| 05/03/2018 |
8-K
| Quarterly results |
| 11/02/2017 |
8-K
| Quarterly results |
| 08/03/2017 |
8-K
| Quarterly results |
| 11/03/2016 |
8-K
| Quarterly results |
| 08/04/2016 |
8-K
| Form 8-K - Current report |
| 05/05/2016 |
8-K
| Quarterly results |
| 11/05/2015 |
8-K
| Quarterly results|
Docs:
|
"OvaScience Reports Third Quarter 2015 Financial Results CAMBRIDGE, Mass., November 5, 2015 - OvaScienceSM , a global fertility company focused on the discovery, development and commercialization of new treatment options, today reported third quarter 2015 financial results and highlighted recent accomplishments. “The recent publication of the AUGMENT patient experiences highlighted the clinical benefit of the treatment in patients with poor fertility prognoses,” said Michelle Dipp, M.D., Ph.D., Chief Executive Officer of OvaScience. “We continue to adapt our commercial operations to reflect rapid changes in the fertility market. Our high-quality, scalable manufacturing and technical operations give us confidence in our ability to expand into new territories, such as Europe and Japan, while ..." |
|
| 08/10/2015 |
8-K
| Quarterly results |
| 05/11/2015 |
8-K
| Quarterly results |
| 11/10/2014 |
8-K
| Quarterly results|
Docs:
|
"OvaScience Reports Third Quarter 2014 Financial Results - Company Ahead of Schedule in Achieving Key 2014 AUGMENTSM Treatment Goal - CAMBRIDGE, Mass., November 10, 2014 — OvaScienceSM , a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, today reported third quarter 2014 financial results. “The interest in our AUGMENT treatment from global fertility specialists has exceeded our expectations, resulting in OvaScience achieving one of its 2014 goals ahead of schedule,” said Michelle Dipp, M.D., Ph.D., Chief Executive Officer of OvaScience. “With more than 60 patients receiving the AUGMENT treatment, we continue to work with many of the world's most forward-thinking fertility experts to bring the AUGMENT treatment to patients ..." |
|
| 08/07/2014 |
8-K
| Quarterly results|
Docs:
|
"OvaScience Reports Second Quarter 2014 Financial Results - AUGMENTSM Treatment Available in Three International Regions; Company More than Halfway Toward Goal of 40 AUGMENT Cycles in 2014 - CAMBRIDGE, Mass., August 7, 2014 — OvaScienceSM , a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, today reported second quarter 2014 financial results and highlighted recent accomplishments. “Our progress this quarter has brought our AUGMENT treatment to women in IVF clinics in three international regions, and we are more than halfway toward executing on our plan for at least 40 AUGMENT cycles in 2014,” said Michelle Dipp, M.D., Ph.D., Chief Executive Officer of OvaScience. “Fertility specialists and their patients now have a treatm..." |
|
| 05/08/2014 |
8-K
| Quarterly results |
| 11/13/2013 |
8-K
| Quarterly results|
Docs:
|
"OvaScience Reports Third Quarter Fiscal 2013 Financial Results CAMBRIDGE, Mass., November 13, 2013 — OvaScienceSM, , a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, today reported financial results for the quarter ended September 30, 2013, as well as recent highlights. “We have continued to develop our EggPCSM technology platform and move forward with our planned international commercial activities for our first product candidate, AUGMENTSM,” said Michelle Dipp, M.D., Ph.D., Chief Executive Officer of OvaScience. “The team remains focused on a number of opportunities to make our products available to patients outside of the U.S., while research and development efforts are yielding enhancements to our EggPC processing ca..." |
|
| 08/13/2013 |
8-K
| Form 8-K - Current report |
| 05/15/2013 |
8-K
| Quarterly results|
Docs:
|
"OvaScience Reports First Quarter Fiscal 2013 Financial Results CAMBRIDGE, Mass., May 15, 2013 — OvaScienceSM, , a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, today reported financial results for the quarter ended March 31, 2013, and highlighted the Company's recent achievements. “OvaScience continued to make progress this quarter, as we moved closer to a planned product launch next year,” said Michelle Dipp, M.D., Ph.D., Chief Executive Officer of OvaScience. “We secured additional capital to support our pipeline and an accelerated international strategy, while expanding our shareholder base to include other top-tier investors. More recently, we achieved our goal of listing our common stock on NASDAQ. We also demonstr..." |
|
| 11/13/2012 |
8-K
| Form 8-K - Current report |
|
|